Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Inducing efficient cross-priming using antigen-coated yeast particles.

Howland SW, Tsuji T, Gnjatic S, Ritter G, Old LJ, Wittrup KD.

J Immunother. 2008 Sep;31(7):607-19. doi: 10.1097/CJI.0b013e318181c87f.

2.

Processing and cross-presentation of individual HLA-A, -B, or -C epitopes from NY-ESO-1 or an HLA-A epitope for Melan-A differ according to the mode of antigen delivery.

Robson NC, McAlpine T, Knights AJ, Schnurr M, Shin A, Chen W, Maraskovsky E, Cebon J.

Blood. 2010 Jul 15;116(2):218-25. doi: 10.1182/blood-2009-10-249458. Epub 2010 Apr 29.

3.

ISCOMATRIX adjuvant induces efficient cross-presentation of tumor antigen by dendritic cells via rapid cytosolic antigen delivery and processing via tripeptidyl peptidase II.

Schnurr M, Orban M, Robson NC, Shin A, Braley H, Airey D, Cebon J, Maraskovsky E, Endres S.

J Immunol. 2009 Feb 1;182(3):1253-9. Erratum in: J Immunol. 2009 Apr 15;182(8):5152.

4.

Cross-presentation of HLA class I epitopes from influenza matrix protein produced in Saccharomyces cerevisiae.

Wadle A, Held G, Neumann F, Kleber S, Wuellner B, Asemissen AM, Kubuschok B, Scheibenbogen C, Breinig T, Meyerhans A, Renner C.

Vaccine. 2006 Sep 11;24(37-39):6272-81. Epub 2006 Jun 14.

PMID:
16860448
5.

Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity.

Tsuji T, Matsuzaki J, Kelly MP, Ramakrishna V, Vitale L, He LZ, Keler T, Odunsi K, Old LJ, Ritter G, Gnjatic S.

J Immunol. 2011 Jan 15;186(2):1218-27. doi: 10.4049/jimmunol.1000808. Epub 2010 Dec 13.

6.

NY-ESO-1 protein glycosylated by yeast induces enhanced immune responses.

Wadle A, Mischo A, Strahl S, Nishikawa H, Held G, Neumann F, Wullner B, Fischer E, Kleber S, Karbach J, Jager E, Shiku H, Odunsi K, Shrikant PA, Knuth A, Cerundolo V, Renner C.

Yeast. 2010 Nov;27(11):919-31. doi: 10.1002/yea.1796.

7.

Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.

Sorensen MR, Holst PJ, Pircher H, Christensen JP, Thomsen AR.

Eur J Immunol. 2009 Oct;39(10):2725-36. doi: 10.1002/eji.200939543.

8.

Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals.

Kreiter S, Selmi A, Diken M, Sebastian M, Osterloh P, Schild H, Huber C, Türeci O, Sahin U.

J Immunol. 2008 Jan 1;180(1):309-18. Erratum in: J Immunol. 2012 Sep 1;189(5):2682.

9.

Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery.

Schnurr M, Chen Q, Shin A, Chen W, Toy T, Jenderek C, Green S, Miloradovic L, Drane D, Davis ID, Villadangos J, Shortman K, Maraskovsky E, Cebon J.

Blood. 2005 Mar 15;105(6):2465-72. Epub 2004 Nov 16.

10.

Factors affecting the efficiency of CD8+ T cell cross-priming with exogenous antigens.

Maecker HT, Ghanekar SA, Suni MA, He XS, Picker LJ, Maino VC.

J Immunol. 2001 Jun 15;166(12):7268-75.

11.

Cross-presentation of NY-ESO-1 cytotoxic T lymphocyte epitope fused to human heat shock cognate protein 70 by dendritic cells.

Susumu S, Nagata Y, Ito S, Matsuo M, Valmori D, Yui K, Udono H, Kanematsu T.

Cancer Sci. 2008 Jan;99(1):107-12. Epub 2007 Nov 7.

12.

KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity.

Skoberne M, Yewdall A, Bahjat KS, Godefroy E, Lauer P, Lemmens E, Liu W, Luckett W, Leong M, Dubensky TW, Brockstedt DG, Bhardwaj N.

J Clin Invest. 2008 Dec;118(12):3990-4001. doi: 10.1172/JCI31350. Epub 2008 Nov 6.

13.

Molecular and cellular requirements for enhanced antigen cross-presentation to CD8 cytotoxic T lymphocytes.

Oizumi S, Strbo N, Pahwa S, Deyev V, Podack ER.

J Immunol. 2007 Aug 15;179(4):2310-7.

16.

Influenza A infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashion.

Wei J, Waithman J, Lata R, Mifsud NA, Cebon J, Kay T, Smyth MJ, Sadler AJ, Chen W.

J Immunol. 2010 Nov 15;185(10):6013-22. doi: 10.4049/jimmunol.1002129. Epub 2010 Oct 18.

17.

Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.

Valmori D, Souleimanian NE, Tosello V, Bhardwaj N, Adams S, O'Neill D, Pavlick A, Escalon JB, Cruz CM, Angiulli A, Angiulli F, Mears G, Vogel SM, Pan L, Jungbluth AA, Hoffmann EW, Venhaus R, Ritter G, Old LJ, Ayyoub M.

Proc Natl Acad Sci U S A. 2007 May 22;104(21):8947-52. Epub 2007 May 15.

19.

Maturation pathways of dendritic cells determine TAP1 and TAP2 levels and cross-presenting function.

López-Albaitero A, Mailliard R, Hackman T, Andrade Filho PA, Wang X, Gooding W, Ferrone S, Kalinski P, Ferris RL.

J Immunother. 2009 Jun;32(5):465-73. doi: 10.1097/CJI.0b013e3181a1c24e.

20.

Induction of cross-priming of naive CD8+ T lymphocytes by recombinant bacillus Calmette-Guerin that secretes heat shock protein 70-major membrane protein-II fusion protein.

Mukai T, Maeda Y, Tamura T, Matsuoka M, Tsukamoto Y, Makino M.

J Immunol. 2009 Nov 15;183(10):6561-8. doi: 10.4049/jimmunol.0803857. Epub 2009 Oct 21.

Supplemental Content

Support Center